Top

Current Neurology and Neuroscience Reports

Published in:

01-09-2014 | Demyelinating Disorders (DN Bourdette and V Yadav, Section Editors)

Autologous Bone Marrow Transplantation for the Treatment of Multiple Sclerosis

Authors: Marta Radaelli, Arianna Merlini, Raffaella Greco, Francesca Sangalli, Giancarlo Comi, Fabio Ciceri, Gianvito Martino

Published in: Current Neurology and Neuroscience Reports | Issue 9/2014

Abstract

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system and represents one of the leading causes of neurologic disability in young adults. Current treatments for MS have shown limited efficacy in patients with either a progressive or an aggressive disease course. Hematopoietic stem cell transplantation (HSCT) has been proposed to control or even cure refractory cases of MS. Indeed, HSCT is able to temporarily eradicate the autoreactive cells and to reset the aberrant immune response to self-antigens. In the last decade, owing to the growing experience in selecting the most appropriate patients to transplant and the recent advances in chemotherapeutic and support regimens, the transplant-related mortality of autologous HSCT in MS patients dropped down to 1,3 % and the progression-free survival ranges from 47 % to 100 %. Altogether, these data support autologous HSCT as a possible second-line therapy for refractory MS.

Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343(13):938–52. doi:10.1056/NEJM200009283431307.PubMedCrossRef

Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129(Pt 3):606–16. doi:10.1093/brain/awl007.PubMedCrossRef

Kremenchutzky M, Cottrell D, Rice G, Hader W, Baskerville J, Koopman W, et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation . Brain. 1999;122(Pt 10):1941–50.PubMedCrossRef

Codarri L, Greter M, Becher B. Communication between pathogenic T-cells and myeloid cells in neuroinflammatory disease. Trends Immunol. 2013;34(3):114–9. doi:10.1016/j.it.2012.09.007.PubMedCrossRef

Comi G. Induction vs escalating therapy in multiple sclerosis: practical implications. Neurol Sci. 2008;29 Suppl 2:S253–5. doi:10.1007/s10072-008-0954-x.PubMedCrossRef

Saccardi R, Di Gioia M, Bosi A. Haematopoietic stem cell transplantation for autoimmune disorders. Curr Opin Hematol. 2008;15(6):594–600. doi:10.1097/MOH.0b013e3283136700.PubMedCrossRef

7.••

Snowden JA, Saccardi R, Allez M, Ardizzone S, Arnold R, Cervera R, et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2012;47(6):770–90. doi:10.1038/bmt.2011.185. Current guidelines for HSCT in autoimmune disorders.PubMedCentralPubMedCrossRef

van Bekkum DW. Stem cell transplantation in experimental models of autoimmune disease. J Clin Immunol. 2000;20(1):10–6.PubMedCrossRef

Marmont AM. Stem cell transplantation for autoimmune disorders. Coincidental autoimmune disease in patients transplanted for conventional indications. Best Pract Res Clin Hematol. 2004;17(2):223–32. doi:10.1016/j.beha.2004.04.004.CrossRef

10.

Burt RK, Padilla J, Begolka WS, Canto MC, Miller SD. Effect of disease stage on clinical outcome after syngeneic bone marrow transplantation for relapsing experimental autoimmune encephalomyelitis. Blood. 1998;91(7):2609–16.PubMed

11.

Pfender N, Saccardi R, Martin R. Autologous hematopoietic stem cell transplantation as a treatment option for aggressive multiple sclerosis. Curr Treat Options Neurol. 2013;15(3):270–80. doi:10.1007/s11940-013-0234-9.PubMedCrossRef

12.

Muraro PA, Douek DC, Packer A, Chung K, Guenaga FJ, Cassiani-Ingoni R, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med. 2005;201(5):805–16. doi:10.1084/jem.20041679.PubMedCentralPubMedCrossRef

13.•

Darlington PJ, Touil T, Doucet JS, Gaucher D, Zeidan J, Gauchat D, et al. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol. 2013;73(3):341–54. doi:10.1002/ana.23784. Observation that HSCT selectively reduces Th17 in MS.PubMedCrossRef

14.

Dubinsky AN, Burt RK, Martin R, Muraro PA. T-cell clones persisting in the circulation after autologous hematopoietic SCT are undetectable in the peripheral CD34+ selected graft. Bone Marrow Transplant. 2010;45(2):325–31. doi:10.1038/bmt.2009.139.PubMedCrossRef

15.

Muraro PA, Robins H, Malhotra S, Howell M, Phippard D, Desmarais C, et al. T-cell repertoire following autologous stem cell transplantation for multiple sclerosis. J Clin Invest. 2014;124(3):1168–72. doi:10.1172/JCI71691.PubMedCentralPubMedCrossRef

16.•

Abrahamsson SV, Angelini DF, Dubinsky AN, Morel E, Oh U, Jones JL, et al. Nonmyeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T-cells in multiple sclerosis. Brain. 2013;136(Pt 9):2888–903. doi:10.1093/brain/awt182. Mechanism of action of nonmyeloablative conditioning in HSCT for MS.PubMedCrossRef

17.

Sun W, Popat U, Hutton G, Zang YC, Krance R, Carrum G, et al. Characteristics of T-cell receptor repertoire and myelin-reactive T-cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain. 2004;127(Pt 5):996–1008. doi:10.1093/brain/awh117.PubMedCrossRef

18.

Cassiani-Ingoni R, Muraro PA, Magnus T, Reichert-Scrivner S, Schmidt J, Huh J, et al. Disease progression after bone marrow transplantation in a model of multiple sclerosis is associated with chronic microglial and glial progenitor response. J Neuropathol Exp Neurol. 2007;66(7):637–49. doi:10.1097/nen.0b013e318093f3ef.PubMed

19.

Metz I, Lucchinetti CF, Openshaw H, Garcia-Merino A, Lassmann H, Freedman MS, et al. Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain. 2007;130(Pt 5):1254–62. doi:10.1093/brain/awl370.PubMedCrossRef

20.

Lu JQ, Joseph JT, Nash RA, Storek J, Stevens AM, Metz LM, et al. Neuroinflammation and demyelination in multiple sclerosis after allogeneic hematopoietic stem cell transplantation. Arch Neurol. 2010;67(6):716–22. doi:10.1001/archneurol.2010.117.PubMedCrossRef

21.

Lu JQ, Storek J, Metz L, Yong VW, Stevens AM, Nash RA, et al. Continued disease activity in a patient with multiple sclerosis after allogeneic hematopoietic cell transplantation. Arch Neurol. 2009;66(1):116–20. doi:10.1001/archneurol.2008.522.PubMedCrossRef

22.

Fassas A, Anagnostopoulos A, Kazis A, Kapinas K, Sakellari I, Kimiskidis V, et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant. 1997;20(8):631–8. doi:10.1038/sj.bmt.1700944.PubMedCrossRef

23.

Comi G, Kappos L, Clanet M, Ebers G, Fassas A, Fazekas F, et al. Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation. BMT-MS Study Group. J Neurol. 2000;247(5):376–82.PubMedCrossRef

24.

Burt RK, Cohen BA, Russell E, Spero K, Joshi A, Oyama Y, et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood. 2003;102(7):2373–8. doi:10.1182/blood-2003-03-0877.PubMedCrossRef

25.

Nash RA, Bowen JD, McSweeney PA, Pavletic SZ, Maravilla KR, Park MS, et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood. 2003;102(7):2364–72. doi:10.1182/blood-2002-12-3908.PubMedCentralPubMedCrossRef

26.

Kozak T, Havrdova E, Pit'ha J, Gregora E, Pytlik R, Maaloufova J, et al. High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. Bone Marrow Transplant. 2000;25(5):525–31. doi:10.1038/sj.bmt.1702180.PubMedCrossRef

27.

Samijn JP, te Boekhorst PA, Mondria T, van Doorn PA, Flach HZ, van der Meche FG, et al. Intense T-cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis. J Neurol Neurosurg Psychiatry. 2006;77(1):46–50. doi:10.1136/jnnp.2005.063883.PubMedCentralPubMedCrossRef

28.

Openshaw H, Lund BT, Kashyap A, Atkinson R, Sniecinski I, Weiner LP, et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol Blood Marrow Transplant. 2000;6(5A):563–75.PubMedCrossRef

29.

Saiz A, Blanco Y, Carreras E, Berenguer J, Rovira M, Pujol T, et al. Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS. Neurology. 2004;62(2):282–4.PubMedCrossRef

30.

Shevchenko JL, Kuznetsov AN, Ionova TI, Melnichenko VY, Fedorenko DA, Kartashov AV, et al. Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis. Exp Hematol. 2012;40(11):892–8. doi:10.1016/j.exphem.2012.07.003.PubMedCrossRef

31.

Shevchenko YL, Novik AA, Kuznetsov AN, Afanasiev BV, Lisukov IA, Kozlov VA, et al. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis. Exp Hematol. 2008;36(8):922–8. doi:10.1016/j.exphem.2008.03.001.PubMedCrossRef

32.•

Mancardi GL, Sormani MP, Di Gioia M, Vuolo L, Gualandi F, Amato MP, et al. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-center experience. Mult Scler. 2012;18(6):835–42. doi:10.1177/1352458511429320. Italian study of autologous HSCT in MS with BEAM/ATG conditioning regimen.

33.

Burman J, Iacobaeus E, Svenningsson A, Lycke J, Gunnarsson M, Nilsson P, et al. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. J Neurol Neurosurg Psychiatry. 2014. doi:10.1136/jnnp-2013-307207.PubMed

34.

Burt RK, Loh Y, Cohen B, Stefoski D, Balabanov R, Katsamakis G, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/ II study. Lancet Neurol. 2009;8(3):244–53. doi:10.1016/S1474-4422(09)70017-1.

35.

Chen B, Zhou M, Ouyang J, Zhou R, Xu J, Zhang Q, et al. Long-term efficacy of autologous haematopoietic stem cell transplantation in multiple sclerosis at a single institution in China. Neurol Sci. 2012;33(4):881–6. doi:10.1007/s10072-011-0859-y.PubMedCrossRef

36.

Fagius J, Lundgren J, Oberg G. Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation. Mult Scler. 2009;15(2):229–37. doi:10.1177/1352458508096875.PubMedCrossRef

37.

Xu J, Ji BX, Su L, Dong HQ, Sun XJ, Liu CY. Clinical outcomes after autologous haematopoietic stem cell transplantation in patients with progressive multiple sclerosis. Chin Med J (Engl). 2006;119(22):1851–5.

38.

Krasulova E, Trneny M, Kozak T, Vackova B, Pohlreich D, Kemlink D, et al. High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single center 10-year experience. Mult Scler. 2010;16(6):685–93. doi:10.1177/1352458510364538.PubMedCrossRef

39.

Hamerschlak N, Rodrigues M, Moraes DA, Oliveira MC, Stracieri AB, Pieroni F, et al. Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/ horse ATG and CY/rabbit ATG. Bone Marrow Transplant. 2010;45(2):239–48. doi:10.1038/bmt.2009.127.

40.

Fassas A, Passweg JR, Anagnostopoulos A, Kazis A, Kozak T, Havrdova E, et al. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol. 2002;249(8):1088–97. doi:10.1007/s00415-002-0800-7.PubMedCrossRef

41.••

Saccardi R, Freedman MS, Sormani MP, Atkins H, Farge D, Griffith LM, et al. A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. Mult Scler. 2012;18(6):825–34. doi:10.1177/1352458512438454. Proposed indications for HSCT in MS patients: patient’s selection, procedures, and outcome assessment.PubMedCentralPubMedCrossRef

42.

Openshaw H, Stuve O, Antel JP, Nash R, Lund BT, Weiner LP, et al. Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Neurology. 2000;54(11):2147–50.PubMedCrossRef

43.••

Fassas A, Kimiskidis VK, Sakellari I, Kapinas K, Anagnostopoulos A, Tsimourtou V, et al. Long-term results of stem cell transplantation for MS: a single-center experience. Neurology. 2011;76(12):1066–70. doi:10.1212/WNL.0b013e318211c537. Outcome of HSCT in MS patients after a median follow-up of 11 years.PubMedCrossRef

44.

Bowen JD, Kraft GH, Wundes A, Guan Q, Maravilla KR, Gooley TA, et al. Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results. Bone Marrow Transplant. 2012;47(7):946–51. doi:10.1038/bmt.2011.208.PubMedCentralPubMedCrossRef

45.

Saccardi R, Kozak T, Bocelli-Tyndall C, Fassas A, Kazis A, Havrdova E, et al. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler. 2006;12(6):814–23.PubMedCrossRef

46.

Fassas A, Anagnostopoulos A, Kazis A, Kapinas K, Sakellari I, Kimiskidis V, et al. Autologous stem cell transplantation in progressive multiple sclerosis–an interim analysis of efficacy. J Clin Immunol. 2000;20(1):24–30.PubMedCrossRef

47.

Saccardi R, Mancardi GL, Solari A, Bosi A, Bruzzi P, Di Bartolomeo P, et al. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood. 2005;105(6):2601–7. doi:10.1182/blood-2004-08-3205.PubMedCrossRef

48.

Mancardi GL, Murialdo A, Rossi P, Gualandi F, Martino G, Marmont A, et al. Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis. Mult Scler. 2005;11(3):367–71.PubMedCrossRef

49.•

Reston JT, Uhl S, Treadwell JR, Nash RA, Schoelles K. Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review. Mult Scler. 2011;17(2):204–13. doi:10.1177/1352458510383609. An updated review and meta-analysis of autologous HSCT studies in MS.PubMedCrossRef

50.

Muraro PA, Douek DC. Renewing the T-cell repertoire to arrest autoimmune aggression. Trends Immunol. 2006;27(2):61–7. doi:10.1016/j.it.2005.12.003.PubMedCrossRef

Title: Autologous Bone Marrow Transplantation for the Treatment of Multiple Sclerosis
Authors: Marta Radaelli
Arianna Merlini
Raffaella Greco
Francesca Sangalli
Giancarlo Comi
Fabio Ciceri
Gianvito Martino
Publication date: 01-09-2014
Publisher: Springer US
Published in: Current Neurology and Neuroscience Reports / Issue 9/2014
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-014-0478-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Autologous Bone Marrow Transplantation for the Treatment of Multiple Sclerosis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2014

Using Structural and Diffusion Magnetic Resonance Imaging To Differentiate the Dementias

Neuromyelitis Optica Spectrum Disorders

The Role of Olfactory Challenge Tests in Incipient Dementia and Clinical Trial Design

The Molecular Landscape of Pediatric Brain Tumors in the Next-Generation Sequencing Era

Intracranial Cystic Lesions: A Review

Hypertonic Saline for the Treatment of Intracranial Hypertension